Stemline Therapeutics Inc (STML) 14.93 $STML
Stemline Therapeutics to Present at the Deutsche Bank 39th Annual Health Care Conference
GlobeNewswire - Wed Apr 30, 6:16AM CDT
Stemline Therapeutics, Inc. (Nasdaq:STML) announced today that Ivan Bergstein, M.D., Stemline's CEO, will present at the Deutsche Bank 39th Annual Health Care Conference on Wednesday, May 7, 2014 at 1:30 PM ET. The conference will be held at the InterContinental Hotel in Boston, MA. A live webcast of the presentation can be viewed on the Company's website at www.stemline.com.
Global T-Cell Leukemia Therapeutics Pipeline Review 2014 - Analysis of 10 Companies & 14 Drug Profiles
M2 - Wed Apr 23, 8:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/943p82/tcell_leukemia) has announced the addition of the "T-Cell Leukemia - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for T-Cell Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for T-Cell Leukemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of T-Cell Leukemia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for T-Cell Leukemia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the T-Cell Leukemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the T-Cell Leukemia pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - Kyowa Hakko Kirin Co., Ltd. - Nippon Kayaku Co., Ltd. - Pfizer Inc. - Celgene Corporation - Mundipharma International Limited - Pharmacyclics, Inc. - Stemline Therapeutics, Inc. - CytImmune Sciences, Inc. - Applied Immune Technologies Ltd Drug Profiles - mogamulizumab - forodesine hydrochloride - lenalidomide - Anti-Tac(Fv)-PE38 Immunotoxin - PF-03084014 - BMS-906024 - PCI-34051 - SL-101 - Lenaldekar - CYT-91000 - NK-314 - Immunotoxins - TCRL Antibodies For HTLV-1 - L1AD3 For more information visit http://www.researchandmarkets.com/research/94...l_leukemia
Low-Grade Glioma Global Clinical Trials Review, H1, 2014
M2 - Tue Apr 15, 2:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kdzfr4/lowgrade_glioma) has announced the addition of the "Low-Grade Glioma Global Clinical Trials Review, H1, 2014" report to their offering. Low-Grade Glioma Global Clinical Trials Review, H1, 2014" provides data on the Low-Grade Glioma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Low-Grade Glioma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Low-Grade Glioma. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies/Organisations Participating in Low-Grade Glioma Therapeutics Clinical Trials - Stemline Therapeutics, Inc. - AROG Pharmaceuticals LLC - National Cancer Institute - University of California, San Francisco - Duke University - Massachusetts General Hospital - Children's Oncology Group - The Hospital for Sick Children - Radiation Therapy Oncology Group - Sun Yat-sen University - Societe Internationale d'Oncologie Pediatrique For more information visit http://www.researchandmarkets.com/research/kd...ade_glioma
Why Stemline Therapeutics (STML) Could Be Positioned for a Slump - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 09, 7:52AM CDT
One such stock that you may want to consider dropping is Stemline Therapeutics
Stemline Therapeutics Announces FDA Acceptance of IND for SL-701, a Synthetic Multi-Peptide Vaccine Targeting Glioma Brain Tumors
GlobeNewswire - Tue Apr 08, 6:00AM CDT
Stemline Therapeutics, Inc. (Nasdaq:STML) announced today that the U.S. Food and Drug Administration (FDA) has accepted the company's Investigational New Drug (IND) application for SL-701, which enables the company to advance SL-701 into a Phase 2 trial of adults with glioblastoma multiforme (GBM) in first recurrence. SL-701 is a subcutaneously-administered cancer vaccine comprised of multiple synthetic peptides engineered for increased immunoreactivity against targets overexpressed on the cancer stem cells (CSCs) and tumor bulk of gliomas, the most common type of brain cancer. It is based on a vaccine developed at the University of Pittsburgh that demonstrated single agent clinical efficacy, including complete responses (CRs) and partial responses (PRs), in Phase 1/2 trials conducted by the university in both adults and children with high-grade gliomas, including GBM. The Stemline-sponsored trial is an 80-100 patient multi-center study, designed to evaluate SL-701 in adults with GBM that has recurred following initial treatment with surgery, radiation, and chemotherapy. Overall response rate and survival are co-primary endpoints.
Stemline Therapeutics to Present at the 13th Annual Needham Healthcare Conference
GlobeNewswire - Mon Apr 07, 6:06AM CDT
Stemline Therapeutics, Inc. (Nasdaq:STML) announced today that Ivan Bergstein, M.D., Stemline's CEO, will present at the 13th Annual Needham Healthcare Conference on Tuesday, April 8, 2014 at 12:10 PM ET. The conference will be held at the Westin Grand Central Hotel in New York, NY. A live webcast of the presentation can be viewed on the Company's website at www.stemline.com.
Stemline Therapeutics Announces Presentation of SL-501 Preclinical Efficacy Data in TKI-Resistant CML at the Annual Meeting of the American Association of Cancer Research (AACR)
GlobeNewswire - Tue Apr 01, 6:03AM CDT
Stemline Therapeutics, Inc. (Nasdaq:STML) announced today that data demonstrating SL-501 inhibits the growth of tyrosine kinase inhibitor (TKI) resistant chronic myeloid leukemia (CML) cells in preclinical models was selected for poster presentation at the Annual Meeting of the American Association for Cancer Research (AACR) Conference, being held April 5-9, 2014 in San Diego, CA. SL-501 is a highly potent targeted therapy directed to the interleukin-3 receptor (IL-3R). SL-501 is a next generation variant of SL-401; SL-401 is currently being advanced in clinical trials of multiple hematologic cancers.
Nasdaq stocks posting largest percentage decreases
AP - Fri Mar 28, 12:32PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
Where are They Now? Biotech IPO Class of 2013, March Edition
Cory Renauer, The Motley Fool - Motley Fool - Wed Mar 26, 5:30PM CDT
This year you can't squeeze a pipette without hitting another biotech offering. The red-hot sector has seen more than 25 IPOs so far this year. Many are doubling and tripling in price in their first days of trading. In a frenzied market like this...
Stemline Therapeutics to Present at the 26th Annual ROTH Conference
GlobeNewswire - Thu Mar 06, 6:09AM CST
Stemline Therapeutics, Inc. (Nasdaq:STML) announced today that Ivan Bergstein, M.D., Stemline's CEO, will present at the 26th Annual ROTH Conference on Tuesday, March 11, 2014 at 2:30 PM PT. The conference will be held at the Ritz-Carlton, Laguna Niguel in Dana Point, CA. A live webcast of the presentation can be viewed on the Company's website at www.stemline.com.
Stemline Therapeutics to Present at Cowen and Company Health Care Conference
GlobeNewswire - Wed Feb 26, 6:00AM CST
Stemline Therapeutics, Inc. (Nasdaq:STML) announced today that Ivan Bergstein, M.D., Stemline's CEO, will present at the Cowen and Company 34th Annual Health Care Conference on Tuesday, March 4, 2014 at 9:20 AM ET. The conference will be held at the Boston Marriott Copley Place in Boston, MA.
Stemline Therapeutics (STML) Worth Watching: Stock Rises 8.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Feb 24, 8:25AM CST
Stemline Therapeutics was a big mover last session, with shares rising over 8%.
5 Stocks Breaking Out on Unusual Volume
at The Street - Mon Feb 24, 8:11AM CST
These stocks trading with big volume are within range of triggering breakout trades.
Stemline Therapeutics to Present at Citi 2014 Global Healthcare and RBC Capital Markets Conferences
GlobeNewswire - Thu Feb 20, 6:00AM CST
Stemline Therapeutics, Inc. (Nasdaq:STML) announced today that it will present at the Citi 2014 Global Healthcare and RBC Capital Markets Global Healthcare conferences in February.
Malignant Glioma - Pipeline Review, H2 2013 Research Report
M2 - Mon Feb 17, 4:04AM CST
Research and Markets (http://www.researchandmarkets.com/research/zr3vfj/malignant_glioma) has announced the addition of the "Malignant Glioma - Pipeline Review, H2 2013" report to their offering. 'Malignant Glioma - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Malignant Glioma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Malignant Glioma. Scope - A snapshot of the global therapeutic scenario for Malignant Glioma. - A review of the Malignant Glioma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Malignant Glioma pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Malignant Glioma Overview Therapeutics Development Late Stage Products Clinical Stage Products Early Stage Products Drug Profiles Eir-060 - Drug Profile Dendritic Cell Vaccine - Drug Profile Dendritic Cell Vaccine - Drug Profile Carboxyamidotriazole Orotate - Drug Profile SL-701 - Drug Profile Dendritic Cell Vaccine - Drug Profile Dendritic Cell Vaccine - Drug Profile SAR-245409 - Drug Profile WT1 Peptide Vaccine - Drug Profile celecoxib Dendritic Cell Vaccine [temozolomide] Radiation Therapy - Drug Profile Dendritic Cell Vaccine - Drug Profile Peptide Vaccine [sargramostim] - Drug Profile ALD-451 - Drug Profile First Generation Attenuated Strain Of Reovirus - Drug Profile Featured News & Press Releases Appendix List of Tables List of Figures Companies Mentioned Sanofi Cytomedix, Inc. Stemline Therapeutics, Inc. EirGen Pharma Ltd. Tactical Therapeutics, Inc For more information visit http://www.researchandmarkets.com/research/zr...ant_glioma About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Stemline Therapeutics (STML) Soars: Stock Up 17.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 12, 7:51AM CST
Stemline Therapeutics, Inc. was a big mover last session, as its shares rose over 17% on the day.
Stemline Therapeutics to Present at the Leerink Global Healthcare Conference
GlobeNewswire - Thu Feb 06, 6:00AM CST
Stemline Therapeutics, Inc. (Nasdaq:STML) announced today that Ivan Bergstein, M.D., Stemline's CEO, will present at the Leerink Global Healthcare Conference on Thursday, February 13, 2014 at 3:30 PM ET. The conference will be held at the Waldorf Astoria in New York City. A live webcast of the presentation can be viewed on the Company's website at www.stemline.com.
Stemline Therapeutics to Present at the 16th Annual BIO CEO & Investor Conference
GlobeNewswire - Tue Feb 04, 6:00AM CST
Stemline Therapeutics, Inc. (Nasdaq:STML) announced today that Ivan Bergstein, M.D., Stemline's CEO, will present at the 16th Annual Biotechnology Industry Organization (BIO) CEO & Investor Conference on Tuesday, February 11, 2014 at 11:30 AM ET. The conference will be held at the Waldorf Astoria in New York on February 10-11, 2014. A live webcast of the presentation can be viewed on the Company's website at www.stemline.com.
Stemline Therapeutics to Present at the Deutsche Bank 39th Annual Health Care Conference
GlobeNewswire - Wed Apr 30, 6:16AM CDT
Stemline Therapeutics, Inc. (Nasdaq:STML) announced today that Ivan Bergstein, M.D., Stemline's CEO, will present at the Deutsche Bank 39th Annual Health Care Conference on Wednesday, May 7, 2014 at 1:30 PM ET. The conference will be held at the InterContinental Hotel in Boston, MA. A live webcast of the presentation can be viewed on the Company's website at www.stemline.com.
Global T-Cell Leukemia Therapeutics Pipeline Review 2014 - Analysis of 10 Companies & 14 Drug Profiles
M2 - Wed Apr 23, 8:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/943p82/tcell_leukemia) has announced the addition of the "T-Cell Leukemia - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for T-Cell Leukemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for T-Cell Leukemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of T-Cell Leukemia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for T-Cell Leukemia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the T-Cell Leukemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the T-Cell Leukemia pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - Kyowa Hakko Kirin Co., Ltd. - Nippon Kayaku Co., Ltd. - Pfizer Inc. - Celgene Corporation - Mundipharma International Limited - Pharmacyclics, Inc. - Stemline Therapeutics, Inc. - CytImmune Sciences, Inc. - Applied Immune Technologies Ltd Drug Profiles - mogamulizumab - forodesine hydrochloride - lenalidomide - Anti-Tac(Fv)-PE38 Immunotoxin - PF-03084014 - BMS-906024 - PCI-34051 - SL-101 - Lenaldekar - CYT-91000 - NK-314 - Immunotoxins - TCRL Antibodies For HTLV-1 - L1AD3 For more information visit http://www.researchandmarkets.com/research/94...l_leukemia
Low-Grade Glioma Global Clinical Trials Review, H1, 2014
M2 - Tue Apr 15, 2:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kdzfr4/lowgrade_glioma) has announced the addition of the "Low-Grade Glioma Global Clinical Trials Review, H1, 2014" report to their offering. Low-Grade Glioma Global Clinical Trials Review, H1, 2014" provides data on the Low-Grade Glioma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Low-Grade Glioma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Low-Grade Glioma. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies/Organisations Participating in Low-Grade Glioma Therapeutics Clinical Trials - Stemline Therapeutics, Inc. - AROG Pharmaceuticals LLC - National Cancer Institute - University of California, San Francisco - Duke University - Massachusetts General Hospital - Children's Oncology Group - The Hospital for Sick Children - Radiation Therapy Oncology Group - Sun Yat-sen University - Societe Internationale d'Oncologie Pediatrique For more information visit http://www.researchandmarkets.com/research/kd...ade_glioma
Why Stemline Therapeutics (STML) Could Be Positioned for a Slump - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 09, 7:52AM CDT
One such stock that you may want to consider dropping is Stemline Therapeutics
Stemline Therapeutics Announces FDA Acceptance of IND for SL-701, a Synthetic Multi-Peptide Vaccine Targeting Glioma Brain Tumors
GlobeNewswire - Tue Apr 08, 6:00AM CDT
Stemline Therapeutics, Inc. (Nasdaq:STML) announced today that the U.S. Food and Drug Administration (FDA) has accepted the company's Investigational New Drug (IND) application for SL-701, which enables the company to advance SL-701 into a Phase 2 trial of adults with glioblastoma multiforme (GBM) in first recurrence. SL-701 is a subcutaneously-administered cancer vaccine comprised of multiple synthetic peptides engineered for increased immunoreactivity against targets overexpressed on the cancer stem cells (CSCs) and tumor bulk of gliomas, the most common type of brain cancer. It is based on a vaccine developed at the University of Pittsburgh that demonstrated single agent clinical efficacy, including complete responses (CRs) and partial responses (PRs), in Phase 1/2 trials conducted by the university in both adults and children with high-grade gliomas, including GBM. The Stemline-sponsored trial is an 80-100 patient multi-center study, designed to evaluate SL-701 in adults with GBM that has recurred following initial treatment with surgery, radiation, and chemotherapy. Overall response rate and survival are co-primary endpoints.
Stemline Therapeutics to Present at the 13th Annual Needham Healthcare Conference
GlobeNewswire - Mon Apr 07, 6:06AM CDT
Stemline Therapeutics, Inc. (Nasdaq:STML) announced today that Ivan Bergstein, M.D., Stemline's CEO, will present at the 13th Annual Needham Healthcare Conference on Tuesday, April 8, 2014 at 12:10 PM ET. The conference will be held at the Westin Grand Central Hotel in New York, NY. A live webcast of the presentation can be viewed on the Company's website at www.stemline.com.
Stemline Therapeutics Announces Presentation of SL-501 Preclinical Efficacy Data in TKI-Resistant CML at the Annual Meeting of the American Association of Cancer Research (AACR)
GlobeNewswire - Tue Apr 01, 6:03AM CDT
Stemline Therapeutics, Inc. (Nasdaq:STML) announced today that data demonstrating SL-501 inhibits the growth of tyrosine kinase inhibitor (TKI) resistant chronic myeloid leukemia (CML) cells in preclinical models was selected for poster presentation at the Annual Meeting of the American Association for Cancer Research (AACR) Conference, being held April 5-9, 2014 in San Diego, CA. SL-501 is a highly potent targeted therapy directed to the interleukin-3 receptor (IL-3R). SL-501 is a next generation variant of SL-401; SL-401 is currently being advanced in clinical trials of multiple hematologic cancers.
Nasdaq stocks posting largest percentage decreases
AP - Fri Mar 28, 12:32PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
Where are They Now? Biotech IPO Class of 2013, March Edition
Cory Renauer, The Motley Fool - Motley Fool - Wed Mar 26, 5:30PM CDT
This year you can't squeeze a pipette without hitting another biotech offering. The red-hot sector has seen more than 25 IPOs so far this year. Many are doubling and tripling in price in their first days of trading. In a frenzied market like this...
Stemline Therapeutics to Present at the 26th Annual ROTH Conference
GlobeNewswire - Thu Mar 06, 6:09AM CST
Stemline Therapeutics, Inc. (Nasdaq:STML) announced today that Ivan Bergstein, M.D., Stemline's CEO, will present at the 26th Annual ROTH Conference on Tuesday, March 11, 2014 at 2:30 PM PT. The conference will be held at the Ritz-Carlton, Laguna Niguel in Dana Point, CA. A live webcast of the presentation can be viewed on the Company's website at www.stemline.com.
Stemline Therapeutics to Present at Cowen and Company Health Care Conference
GlobeNewswire - Wed Feb 26, 6:00AM CST
Stemline Therapeutics, Inc. (Nasdaq:STML) announced today that Ivan Bergstein, M.D., Stemline's CEO, will present at the Cowen and Company 34th Annual Health Care Conference on Tuesday, March 4, 2014 at 9:20 AM ET. The conference will be held at the Boston Marriott Copley Place in Boston, MA.
Stemline Therapeutics (STML) Worth Watching: Stock Rises 8.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Feb 24, 8:25AM CST
Stemline Therapeutics was a big mover last session, with shares rising over 8%.
5 Stocks Breaking Out on Unusual Volume
at The Street - Mon Feb 24, 8:11AM CST
These stocks trading with big volume are within range of triggering breakout trades.
Stemline Therapeutics to Present at Citi 2014 Global Healthcare and RBC Capital Markets Conferences
GlobeNewswire - Thu Feb 20, 6:00AM CST
Stemline Therapeutics, Inc. (Nasdaq:STML) announced today that it will present at the Citi 2014 Global Healthcare and RBC Capital Markets Global Healthcare conferences in February.
Malignant Glioma - Pipeline Review, H2 2013 Research Report
M2 - Mon Feb 17, 4:04AM CST
Research and Markets (http://www.researchandmarkets.com/research/zr3vfj/malignant_glioma) has announced the addition of the "Malignant Glioma - Pipeline Review, H2 2013" report to their offering. 'Malignant Glioma - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Malignant Glioma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Malignant Glioma. Scope - A snapshot of the global therapeutic scenario for Malignant Glioma. - A review of the Malignant Glioma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Malignant Glioma pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: Introduction Malignant Glioma Overview Therapeutics Development Late Stage Products Clinical Stage Products Early Stage Products Drug Profiles Eir-060 - Drug Profile Dendritic Cell Vaccine - Drug Profile Dendritic Cell Vaccine - Drug Profile Carboxyamidotriazole Orotate - Drug Profile SL-701 - Drug Profile Dendritic Cell Vaccine - Drug Profile Dendritic Cell Vaccine - Drug Profile SAR-245409 - Drug Profile WT1 Peptide Vaccine - Drug Profile celecoxib Dendritic Cell Vaccine [temozolomide] Radiation Therapy - Drug Profile Dendritic Cell Vaccine - Drug Profile Peptide Vaccine [sargramostim] - Drug Profile ALD-451 - Drug Profile First Generation Attenuated Strain Of Reovirus - Drug Profile Featured News & Press Releases Appendix List of Tables List of Figures Companies Mentioned Sanofi Cytomedix, Inc. Stemline Therapeutics, Inc. EirGen Pharma Ltd. Tactical Therapeutics, Inc For more information visit http://www.researchandmarkets.com/research/zr...ant_glioma About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Stemline Therapeutics (STML) Soars: Stock Up 17.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 12, 7:51AM CST
Stemline Therapeutics, Inc. was a big mover last session, as its shares rose over 17% on the day.
Stemline Therapeutics to Present at the Leerink Global Healthcare Conference
GlobeNewswire - Thu Feb 06, 6:00AM CST
Stemline Therapeutics, Inc. (Nasdaq:STML) announced today that Ivan Bergstein, M.D., Stemline's CEO, will present at the Leerink Global Healthcare Conference on Thursday, February 13, 2014 at 3:30 PM ET. The conference will be held at the Waldorf Astoria in New York City. A live webcast of the presentation can be viewed on the Company's website at www.stemline.com.
Stemline Therapeutics to Present at the 16th Annual BIO CEO & Investor Conference
GlobeNewswire - Tue Feb 04, 6:00AM CST
Stemline Therapeutics, Inc. (Nasdaq:STML) announced today that Ivan Bergstein, M.D., Stemline's CEO, will present at the 16th Annual Biotechnology Industry Organization (BIO) CEO & Investor Conference on Tuesday, February 11, 2014 at 11:30 AM ET. The conference will be held at the Waldorf Astoria in New York on February 10-11, 2014. A live webcast of the presentation can be viewed on the Company's website at www.stemline.com.
